EPRX
Eupraxia Pharmaceuticals Inc.
Healthcare — Biotechnology
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Price History
Fundamentals
| Market Cap | $438.34M |
| P/E Ratio (TTM) | - |
| Forward P/E | -7.46 |
| EPS (TTM) | $-1.05 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -54.52% |
| Debt/Equity | 1.47 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $16.28 |
| Analysts | 9 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 70.1 |
| Beta | 1.48 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $9.32 |
| 52-Week Low | $4.88 |
| 50-Day Avg | $6.83 |
| 200-Day Avg | $6.94 |
| Avg Volume | 285.4K |
| Volume | 256.6K |
Performance Analysis
BULLISHEPRX shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:08 UTC
Back to Screener Export Report